Gender | N% |
---|---|
Male | 8 (53,3%) |
Female | 7 (46,7%) |
Median age in years | 12.4 |
Primary tumor location | |
Extremity | 9 (60%) |
Axis | 6 (40%) |
Metastasis at initial diagnosis | 11 |
Site of metastases at diagnosis | |
Lungs | 9 (81,8%) |
Lungs + Bones | 2 (18,2%) |
Local treatment at diagnosis | |
Surgery only | 6 (40%) |
RTX only | 3 (20%) |
Both | 6 (40%) |
Neoadjuvant chemotherapy | |
VIDE regimen | 14 (93,3%) |
CAV/ETIF regimen | 1 (6,7%) |
Bone marrow transplant in 1 CR | 7 (47%) |
Follow-up | |
Relapse | 11 (73,3%) |
Progression on primary therapy | 1 (6,7%) |
Median TTR in months | 9.9 |
Patient nb. | Stage at dlagn. | Patient characteristic according to the treatment | Intention of trofosfamide maintenance therapy | Status of disease before trofosfamide | Nb. of courses | Best response | Toxicity (grade 2-4) | Reason for stopping therapy | Treatment after trofosfamlde | Status (last follow up In years) |
---|---|---|---|---|---|---|---|---|---|---|
1 | Met. | 1st line | radical | CR | 8 | CR | renal dysfunction | renal toxicity | - | NED (2.0) |
2 | Met. | 1st line | radical | CR | 4 | CR | renal dysfunction | renal toxicity | - | NED (1.4) |
3 | Met. | progression on the 1st line | radical | CR | 10 | CR | renal dysfunction | renal toxicity | - | NED (4.3) |
4 | Loc. | relapse | radical | CR | 12 | CR | none | end of treatment | - | NED (6.3) |
5 | Loc. | relapse | palliative | PD | 2 | PD | none | death | - | DOD (7.7) |
6 | Loc. | relapse | Palliative | PD | 2 | PD | none | death | - | DOD (9.9) |
7 | Met. | relapse | radical | CR | 6 | CR | none | still in treatment | - | NED (3.3) |
8 | Loc. | relapse | palliative | PD | 2 | PD | none | progression | VP | DOD (5.7) |
9 | Met. | 1st line | radical | CR | 1 | CR | leucopenia | marrow toxicity | - | NED (3.2) |
10 | Met. | relapse | radical | CR | 13 | CR | none | end of treatment | - | NED (7.6) |
11 | Met. | relapse | palliative | PD | 5 | PD | none | death | - | DOD (3.5) |
12 | Met. | relapse | radical | CR | 8 | CR | none | end of treatment | - | NED (5.2) |
13 | Met. | relapse | palliative | SD | 8 | PD | none | progression | VN/CTX, T | AWD (3.9) |
14 | Met. | relapse | radical | CR | 3 | PD | none | progression | TC. HD-IFO | AWD (1.5) |
15 | Met. | relapse | radical | CR | 11 | CR | none | end of treatment | - | NED (3.9) |